Yogesh Radke

Given the underperformance in IT and Pharma space, the two can be the ‘hiding places‘ and may outperform in the broader market, says Yogesh Radke of Edelweiss Securities.

Rollover data suggests mkt may head higher in Sept: Edelweiss

61 percent F&O rollover on Nifty before expiry. Market may head upwards from these levels for the September series, says Yogesh Radke of Edelweiss Securities.

Nifty could slip to 7800 in November F&O series: Edelweiss

The roll over cost for the November series is around 45-50 basis points compared to an average of around 70 basis points during a bull market, indicating that traders are cautious about carrying forward their long positions, says Yogesh Radke of Edelweiss Securities

Prefer Reliance Industries, SBI, BoB: Yogesh Radke

Yogesh Radke, Head of Quantitative Research at Edelweiss Securities prefers Reliance Industries, State Bank of India and Bank of Baroda.

Pharma, IT may outperform in April series too: Edelweiss

With IT and pharma still continuing to see interest, the next series too looks promising for them, says Yogesh Radke, head of quantitative research at Edelweiss Securities.

Yogesh Radke positive on YES Bank, target Rs 885

Yogesh Radke - Head of Quantitative Research at Edelweiss Securities has a positive view on YES Bank and has a target price of Rs 885 in the short term.

Buy YES Bank with short-term target at Rs 885: Edelweiss

Idea, however, has not been performing too well over the last couple of days. Fundamental concerns continue to plague to stock, says Yogesh Radke, head of quantitative research, Edelweiss Securities.

Nifty likely to correct; unwind longs: Yogesh Radke

The leverage positions in the Futures market have gone as high as Rs 1 lakh crore, says Yogesh Radke, head of quantitative research at Edelweiss Securities.

See correction in Zee Entertainment: Yogesh Radke

Yogesh Radke - Head of Quantitative Research at Edelweiss Securities is of the view that Zee Entertainment may correct from these levels.

Prefer Bata India, Colgate Palmolive: Yogesh Radke

According to Yogesh Radke, head of quantitative research at Edelweiss Securities, one may keep Bata India, Colgate Palmolive, Cummins India and Nestle India in the portfolio.

Heavy borrowing cost signals aggressive shorts in BHEL

Yogesh Radke, head of quantitative research at Edelweiss Securities, said interest on BHEL under the securities lending and borrowing scheme (SLBS) has surged.

Book profit in CIL, see no near-term trigger: Edelweiss

Yogesh Radke, Head of Quantitative Research at Edelweiss Securities advises booking profit in Coal India because the dividend expectation trigger is done with and does not see any more short-term triggers.

GSK Pharma to perform even post open offer; hold: Edelweiss

According to Yogesh Radke, long-term retail investor can continue to hold on GSK pharma in his portfolio. Or if he wants to exit, it is better to exit onscreen rather than tendering into the offer.

Mkt rally brief; Nifty to hit 5750 post Sept expiry: Expert

The currency hedging cost has gone up from around 80 bps to nearly 100-110 bps, says Yogesh Radke, Head-Quantative Research, Edelweiss Securities.

Hexaware good play from 3-month perspective: Edelweiss Sec

Yogesh Radke, head-quantative research, Edelweiss Securities sees Hexaware Technologies as a good play on back of the open offer and one can expect a 10 percent gain from a three month timeframe.

See upside in Wipro: Edelweiss Securities

Yogesh Radke, Head-Quantative Research, Edelweiss Securities feels that post demerger the interest among the investors would be in the Wipro and we may see upward movement in the counter.

Wipro likely to move up post demerger: Edelweiss

Yogesh Radke, Head-Quantative Research, Edelweiss Securities, Edelweiss, believes that in the Wipro demerger announcement, converting back its shares into the Wipro Ltd. is the best option.

MNCs looking at easy ways to reduce stake: Edelweiss

Yogesh Radke, Senior Manager, Institutional Equities - Quantitative Research Desk, Edelweiss is of the opinion that most MNCs still prefer delisting. However, high valuations are making them think whether it is a better option to delist themselves by giving a hefty premium for a small stake.

Alfa Laval retail holding above acceptable limit: Edelweiss

Alfa Laval considered voluntary delisting of its Indian business from the bourses in its board meeting on September 19. Yogesh Radke, senior manager (institutional equities) of Quantitative Research Desk at Edelweiss Capital told CNBC-TV18 that Alfa Laval’s probability to complete the delisting is slightly low as its retail holding is high.

How to play buybacks, open offers?

Buybacks, open offers, delisting very often in the case of many global MNC, what does that constitute and how does an investor take a studied call on whether or not they should tender or exit as the case maybe or actually stay invested? Experts discuss.

No play left in Cairn India open offer: Edelweiss Capital

Yogesh Radke, Senior Manager (Institutional Equities - Quantitative Research Desk) at Edelweiss Capital, in an interview with CNBC-TV18’s Udayan and Mitali Mukherjee, gave his strategy on investing in various scenarios.